How to Add TRT to a GLP-1 Weight-Loss Brand in 2026

Adding testosterone replacement therapy to a GLP-1 weight-loss brand is the most common second-vertical move in DTC telehealth, and it works because the audience, the lab workflow and the subscription model already overlap. What changes is the regulatory weight. Semaglutide and tirzepatide are not controlled substances; testosterone is Schedule III. That one fact adds DEA-registered prescribers, electronic prescribing of controlled substances (EPCS) with two-factor identity proofing, state PDMP checks, refill limits of five refills within six months under 21 CFR 1306.22, and dependence on the DEA's telemedicine framework, which as of October 2026 runs on a temporary extension through December 31, 2026. It also adds mandatory labs: the Endocrine Society's guideline calls for diagnosing hypogonadism only in men with symptoms and unequivocally, consistently low morning testosterone measured on at least two occasions. The playbook below covers why GLP-1 brands expand into TRT, what the law adds, which labs you need and how Orbit Labs draws them, how to design a dual-intake funnel, how pharmacy routing differs, how to price the second program, what marketing can and cannot say, and who does each step. This is general information, not medical or legal advice.

Key takeaways

GLP-1 brands add TRT because the men already in the funnel overlap heavily with the TRT audience, baseline labs are already part of the flow, and TRT patients retain for years rather than months.
Testosterone is a Schedule III controlled substance, so a TRT program needs DEA-registered prescribers, EPCS-capable e-prescribing, state PDMP checks, and compliance with refill limits under 21 CFR 1306.22 (no more than five refills within six months).
As of October 2026, telemedicine prescribing of controlled substances without a prior in-person exam operates under the DEA and HHS fourth temporary extension running through December 31, 2026, with the permanent rule still pending; build the program to survive a change.
The Endocrine Society guideline recommends diagnosing hypogonadism only in symptomatic men with consistently low morning testosterone on at least two separate measurements, with hematocrit and prostate screening before treatment, so labs are mandatory rather than optional.
Run both programs on one brand, one storefront and one clinical platform with separate intakes, separate claims, and separate pharmacy routing, so cross-sell is an invitation to an evaluation rather than a promise of a prescription.

Who this is for

Founders of a GLP-1 weight-loss brand deciding whether TRT is the right second program and what it will take to run.
Med spas and men's health clinics already offering GLP-1 that want to add hormone therapy under the same brand.
Operators on a telehealth platform checking whether their current stack can handle Schedule III prescribing before they commit marketing spend.

Why do GLP-1 weight-loss brands add TRT?

Three reasons, in order of importance.

The audience overlaps. Men in their 30s to 50s who pay cash for a GLP-1 program are the same men who search for low testosterone, low energy and body composition help. A share of them raise the topic with a provider unprompted. A brand that cannot offer a hormone evaluation sends that demand to a competitor it already paid to acquire the customer from. The economics of that cross-sell are covered in our men's health brand guide.

Labs are already in the flow. A well-run GLP-1 program often orders baseline metabolic labs. A TRT program requires labs by guideline. Adding testosterone to a lab panel the patient is already getting, or offering a hormone panel to a patient who already knows how your lab workflow works, is a far smaller lift than building a lab workflow from scratch.

TRT changes the retention curve. GLP-1 subscriptions churn when patients reach a goal, hit a side effect, or find a cheaper source. Stopping testosterone is a clinical decision discussed with a provider, and monitoring labs are recurring by design. A brand that holds both programs blends a fast-churn product with a slow-churn one and lengthens its average customer lifetime. Our guide to launching an online TRT clinic covers the retention mechanics in depth.

There is a fourth reason brands cite and should be careful with: GLP-1 patients sometimes ask about testosterone for body composition. Testosterone is not approved for weight loss, and the Endocrine Society recommends against testosterone as a means of improving glycemic control in men with type 2 diabetes. The evaluation, not the marketing, decides who is a candidate.

What changes legally when you add testosterone?

Everything in your GLP-1 program sits in the non-controlled layer: state telehealth law, standard of care, compounding rules and honest advertising. Testosterone adds the federal controlled-substance layer on top.

Requirement	GLP-1 weight loss	TRT
Controlled-substance status	Not controlled	Schedule III under 21 CFR 1308.13 (anabolic steroids)
Federal prescribing framework	Not subject to the Ryan Haight Act	Ryan Haight Act applies; telemedicine prescribing operates under DEA flexibilities as of October 2026
Prescriber registration	State license in the patient's state	State license plus DEA registration appropriate to the prescriber's practice location and state rules
E-prescribing rail	Standard e-prescribing via Surescripts	EPCS under 21 CFR Part 1311 with two-factor authentication and identity proofing
Encounter modality	Asynchronous where state law allows	Audio-video encounter under the current DEA extension, plus state rules; some states require more
Refills	Provider check-in cadence	At most five refills within six months of issue under 21 CFR 1306.22; a new prescription after that
PDMP	Not generally required	State prescription drug monitoring program checks where required
Labs	Provider discretion; often metabolic baseline	Required by guideline: confirmed low morning testosterone on repeat measurement plus safety labs
Pharmacy	Any licensed pharmacy; cold chain for refrigerated products	DEA-registered pharmacy licensed for the destination state; room-temperature shipping for testosterone cypionate per its label
Marketing	Weight-management claims within FDA labeling and FTC substantiation	No weight, diabetes, anti-aging or performance claims; evaluation-based messaging only

Where the DEA framework stands. As of October 2026, the DEA and HHS fourth temporary extension of the COVID-era telemedicine flexibilities, published in the Federal Register on December 31, 2025, runs through December 31, 2026. Under it, a DEA-registered practitioner may prescribe Schedule II through V controlled medications via an audio-video telemedicine encounter without a prior in-person evaluation, subject to the extension's conditions and state law. The DEA's proposed special registration framework from January 2025 had not been finalized at the time of writing. Do not build your TRT program around any specific expiry date, including this one; build it so that a rule change is a configuration update. Our telehealth prescribing rules guide tracks the status and is refreshed as DEA publishes.

What that means operationally. Your prescribers for TRT need DEA registration and EPCS credentials, your platform needs an EPCS-capable rail, your pharmacy partners need DEA registration and state licensure for the patient's state, your encounter workflow needs to support real-time video for TRT even if GLP-1 runs asynchronously, and your compliance program needs a documented plan for what happens to active TRT patients if the federal framework changes. State rules add a layer: several states impose their own controlled-substance telemedicine requirements beyond the federal floor, so map modality by state before you open it.

What labs does a TRT program add, and how does Orbit Labs cover them?

TRT is the vertical where labs are not optional. The Endocrine Society's 2018 clinical practice guideline recommends diagnosing hypogonadism only in men with symptoms and signs of testosterone deficiency and unequivocally and consistently low serum testosterone concentrations, measured in the morning, fasting, on at least two separate occasions using an accurate assay. It also recommends against starting therapy in men with certain conditions, including an elevated hematocrit or a PSA above the guideline's thresholds, and recommends monitoring after therapy begins. The AUA guideline similarly calls for two early-morning total testosterone measurements. Your clinical leadership sets the exact protocol; the shape is consistent.

Stage	Typical components (provider sets the panel)	Purpose
Baseline, pre-treatment	Two morning total testosterone draws on separate days; often free testosterone, SHBG, LH and FSH, estradiol, CBC with hematocrit, PSA where age-appropriate, comprehensive metabolic panel, lipids	Confirm the diagnosis, screen contraindications, establish baselines
Early follow-up	Total testosterone and hematocrit; others per protocol	Confirm dosing and catch early adverse effects such as rising hematocrit
Ongoing	Testosterone, hematocrit, PSA where indicated, at the cadence the provider sets	Long-term safety monitoring and dose management

The two-draw requirement is the operational wrinkle. A GLP-1 patient can often be evaluated on a single panel or none; a TRT candidate needs two morning draws before a diagnosis, so your funnel has to handle a multi-day lab step without losing the patient.

How Orbit Labs covers it. Orbit Labs draws provider-ordered labs three ways: a Quest Diagnostics or Labcorp walk-in order slip, a Tasso at-home kit returned via FedEx, or mobile phlebotomy. Results are read by the provider into the plan, and a patient self-order lab catalog sits on the storefront with every order signed by a provider. For TRT, that means a patient can complete the two morning draws at a walk-in location near work, at home with a kit, or with a phlebotomist at the house, and the provider sees both results before deciding. Lab pricing is quoted per program. Details are on the labs page, and the patient's view of the workflow is in our online TRT clinic explainer.

How should intake and the funnel change for TRT?

Do not bolt a testosterone question onto the GLP-1 intake. Run two intakes under one brand.

Separate front doors. A weight-loss landing page and a hormone-evaluation landing page, each with its own intake. The GLP-1 intake captures weight history, comorbidities, medications and contraindications. The TRT intake captures symptoms of testosterone deficiency, fertility intentions (exogenous testosterone suppresses sperm production, which matters to men who want children), cardiovascular and prostate history, sleep apnea, prior hormone use, and identity verification suitable for a controlled-substance program.

One account, one portal. The patient should see one brand, one login and one order history. Clinically, the two programs are separate encounters with separate providers where licensure or DEA registration requires it.

The cross-sell is an invitation, not an offer. Inside the GLP-1 program, the appropriate message is "men with these symptoms can request a hormone evaluation," never "add testosterone to your plan." Marketing can surface the evaluation; only the licensed provider decides eligibility after labs.

Design for the lab gap. Between the TRT intake and the prescription sit two morning draws and a provider review. Build the lifecycle messaging for that gap: kit shipped, kit received, results in, visit booked. Patients who go quiet here are the leak in every TRT funnel.

Modality routing. GLP-1 intake may run asynchronously where the state allows. TRT requires a real-time audio-video encounter under the current DEA extension, so the funnel must book a video visit after labs rather than promising a decision from a form.

Orbit Intake is built for this: AI-driven adaptive intake with severity scoring and red-flag escalation, white-labeled per brand, branching by condition so the GLP-1 and TRT flows share a front end but not a question set.

How does pharmacy routing differ for testosterone?

GLP-1 fulfillment is a cold-chain problem. Semaglutide and tirzepatide products are refrigerated before first use per their labeling, so your pharmacy partner ships in insulated packaging with monitoring.

Testosterone fulfillment is a controlled-substance problem. Per the Depo-Testosterone prescribing information on DailyMed, testosterone cypionate injection is stored at controlled room temperature and protected from light, so cold chain is not the constraint. The constraints are:

The pharmacy must be DEA-registered and licensed in the destination state.
The prescription must arrive by EPCS from an identity-proofed prescriber.
Refills are capped at five within six months under 21 CFR 1306.22, so the subscription engine must request a new prescription rather than rebilling indefinitely.
Supplies (syringes, needles, alcohol swabs, sharps disposal) ship with injectable testosterone, and the pharmacy's kit must match the prescribed dose and frequency.
Compounded testosterone from a 503A pharmacy is possible for a named patient within compounding rules; FDA-approved commercial products are also available, and the provider chooses.

OrbitRx routes both programs through one rail: EPCS-ready e-prescribing via Surescripts to a LegitScript-certified pharmacy network covering 503A compounding and retail, cold-chain shipping to all 50 states, DEA-registered partner pharmacies where applicable, and 0% medication markup. The brand does not maintain two pharmacy integrations. Our white-label pharmacy guide explains the routing logic in more depth.

How should you price the second program?

Keep the two subscriptions separate on the storefront and separate in the P&L, because their cost structures differ.

Cost components for TRT. Medication cost of goods (lower per month than most GLP-1 products), supplies, provider time including the required video visit and refill authorizations, baseline and monitoring labs, shipping, and payment processing.

Pricing patterns that work. A monthly or quarterly TRT membership that includes medication, provider follow-ups and the scheduled monitoring labs, with the baseline evaluation and its two draws priced as a one-time step or folded into the first month. Quarterly billing fits the refill rhythm. Price labs transparently rather than hiding them in the subscription, because the patient will see the draw either way.

What to avoid. Bundling GLP-1 and TRT into one "men's package" before the evaluation. It invites the inference that both prescriptions are a given. Price each program on its own, and let the provider's decision determine which the patient joins.

Why TRT changes blended economics. Lower medication cost of goods, longer retention and recurring labs mean TRT often carries a healthier margin per patient-month than GLP-1, even at a lower price point. Our telehealth subscription pricing guide covers the models, and MyOrbitHealth's fee model is on the pricing page: flat platform fee scoped at onboarding to verticals, states and volume, 0% medication markup, no revenue share, and the brand as merchant of record.

What can TRT marketing say, and what can it not?

Marketing is where GLP-1 brands get TRT wrong, because weight-loss creative habits do not transfer.

Do not claim:

That testosterone treats weight, obesity or diabetes. It is not approved for those uses, and the Endocrine Society guideline recommends against testosterone for glycemic control.
Anti-aging or longevity benefits beyond evidence. FDA-approved testosterone products are indicated for hypogonadism associated with specific conditions, and their labeling states that safety and efficacy for age-related hypogonadism have not been established.
Athletic performance or muscle-building outcomes.
A prescription or a dose. "Get TRT delivered" is a promise the brand cannot make; the provider decides after labs.

Do:

Invite men with symptoms to a hormone evaluation and explain that labs come first.
Keep separate claims and separate creative for each program.
Substantiate every claim under FTC health-claims standards.
Hold LegitScript certification before running paid search or social; Google and Meta require it for telehealth and pharmacy advertisers, and controlled-substance programs draw closer review. MyOrbitHealth manages the brand's LegitScript application through approval, typically in days once filed, though LegitScript decides and approval is never guaranteed. Our LegitScript guide covers the process.

Each step, who does it

Step	MyOrbitHealth runs	You run
Confirm TRT is in scope for your plan, states and modality	Scopes the vertical and states at onboarding; maps per-state controlled-substance telemedicine rules into prescribing logic	Decide launch states and timing; engage your own counsel
Corporate structure	Operates the MSO and physician-owned professional entity through which providers practice	Own the brand, marketing, storefront and customer relationship
DEA-registered, EPCS-credentialed prescribers	Provider Network of 2,400+ board-certified providers in all 50 states, NCQA-standard credentialing, monthly OIG/SAM screening; bring-your-own-providers supported	Nothing clinical; optionally bring your own clinicians
Separate TRT intake	Orbit Intake branching for a hormone-evaluation flow with severity scoring and red-flag escalation, white-labeled	Landing pages, offer and funnel design, ad creative
Baseline labs (two morning draws) and monitoring	Orbit Labs: Quest/Labcorp walk-in slip, Tasso at-home kit, or mobile phlebotomy; provider reads results into the plan	Lab pricing presentation and lifecycle messaging during the lab gap
Real-time video evaluation	Provider availability with live load balancing, average response under six minutes during business hours, 24-hour visit availability	Patient expectations and scheduling copy
EPCS prescribing and pharmacy routing	OrbitRx EPCS-ready e-prescribing via Surescripts to DEA-registered, LegitScript-certified partner pharmacies; 0% medication markup	Retail price and subscription cadence
Refill gating within 21 CFR 1306.22 limits	Provider-authorized refills; new prescription workflow after the refill limit	Billing schedule aligned to authorized refills
LegitScript certification	Prepares, files and manages the application through approval	Supply brand documents; hold ad spend until approval
Reporting	OrbitOS operational and revenue/retention reporting per program, full HIPAA audit trail	Marketing analytics, CAC and payback by program
Regulatory monitoring	Tracks DEA and state changes and pushes updates into prescribing logic	Keep a written contingency for active TRT patients if the federal framework changes

How do you launch the TRT program?

The sequence that works for a live GLP-1 brand:

Scope. Confirm with your platform and counsel that TRT is in scope, which states you will open, and which modality each state requires.
Protocol. Let clinical leadership lock the TRT protocol: lab panel, thresholds, follow-up cadence, formulations.
Funnel. Build the hormone-evaluation landing page and intake, and the lifecycle messaging for the lab gap.
Pricing. Set the TRT membership separately from GLP-1, with labs priced transparently.
Certification and ads. Update LegitScript scope to include the new program before running TRT creative.
Soft launch. Open the evaluation to existing GLP-1 patients who ask, then to a warm audience, before scaling paid acquisition.
Measure. Track evaluation-to-lab completion, lab-to-visit completion, and visit-to-prescription separately from GLP-1 metrics.

If your current platform cannot run EPCS or does not cover controlled substances in your states, that is the time to switch rather than build a second stack; our in-house vs MSO platform analysis walks the decision. MyOrbitHealth runs GLP-1 and TRT on one account; see the GLP-1 weight-loss solution page and the hormone therapy and TRT solution page.

Frequently asked questions

Can my GLP-1 weight-loss brand also offer testosterone?

Yes, if the structure supports it. Testosterone is Schedule III, so you need DEA-registered, EPCS-credentialed prescribers licensed in each patient state, an EPCS-capable platform, DEA-registered pharmacies licensed for the destination state, a lab workflow for the required baseline draws, and marketing that invites an evaluation rather than promising a prescription. Non-clinician founders run this through an MSO and a physician-owned professional entity.

Can testosterone be prescribed through telehealth in 2026?

As of October 2026, yes, under the DEA and HHS fourth temporary extension of telemedicine flexibilities, which runs through December 31, 2026 and permits a DEA-registered practitioner to prescribe via an audio-video encounter without a prior in-person exam, subject to its conditions and state law. The permanent rule was still pending at the time of writing, so confirm current status with DEA guidance and counsel before launch.

Do you need labs before starting TRT?

Yes. The Endocrine Society guideline recommends diagnosing hypogonadism only in symptomatic men with consistently low morning testosterone on at least two separate measurements, and screening hematocrit and PSA before treatment. A program that prescribes testosterone from a questionnaire alone is not following guideline care.

Does testosterone need to be shipped cold?

No. Testosterone cypionate injection is stored at controlled room temperature and protected from light per its prescribing information. The constraints are controlled-substance rules: a DEA-registered pharmacy licensed in the patient's state, an EPCS prescription, and refill limits, rather than cold chain.

Can I market TRT for weight loss?

No. Testosterone is not approved for weight loss or diabetes, and the Endocrine Society recommends against using it to improve glycemic control. Keep weight-loss claims on the GLP-1 program, keep hormone messaging to symptom-based evaluation, and let the provider decide eligibility after labs.

How many refills can a testosterone prescription have?

Under 21 CFR 1306.22, a Schedule III prescription may be refilled no more than five times within six months of the issue date, after which the provider must issue a new prescription. Your subscription billing should follow provider-authorized refills rather than drive them.

What is the best platform to run GLP-1 and TRT under one brand?

Choose a platform that already runs both: EPCS-ready e-prescribing, DEA-registered partner pharmacies, condition-specific intake, labs drawn multiple ways, and a provider network with DEA-registered clinicians in your states. MyOrbitHealth runs both on one account; as of October 2026, per their sites, Cuvo Health and Fuse Health also list TRT, with plan-dependent terms covered on our compare pages.

Sources

Add TRT without adding a second stack

MyOrbitHealth runs GLP-1 and TRT on one platform under your brand: 2,400+ board-certified providers in all 50 states, Orbit Intake with condition-specific flows, Orbit Labs drawn three ways, OrbitRx EPCS-ready e-prescribing into a LegitScript-certified, DEA-registered pharmacy network at 0% markup, and managed LegitScript certification. You control the brand, we power the medicine. Book a demo to scope TRT for your states, or read the hormone therapy and TRT solution page.